Trametinib-induced left ventricular dysfunction in a child with relapsed neuroblastoma Journal Article

Authors: Modak, S.; Asante-Korang, A.; Steinherz, L. J.; Grana, N.
Article Title: Trametinib-induced left ventricular dysfunction in a child with relapsed neuroblastoma
Abstract: The MEK inhibitor trametinib is globally approved for metastatic melanoma harboring BRAF mutations. There are no reports thus far on its use in children. Exome sequencing on a relapsed tumor sample from an 11-year-old male with progressive, multiply relapsed stage 4 neuroblastoma revealed NRASQ61K mutation. After demonstration of normal cardiac function, he was started on oral trametinib. On day 13 of treatment, echocardiogram showed moderate left ventricular dysfunction. Trametinib was discontinued on day 15 and oral lisinopril was started. Left ventricular function recovered to baseline 37 days after discontinuing trametinib. However, neuroblastoma showed further progression. © 2015 Wolters Kluwer Health, Inc. All rights reserved.
Keywords: child; school child; sequence analysis; somatic mutation; cancer recurrence; case report; cancer growth; drug withdrawal; heart left ventricle failure; cancer palliative therapy; childhood cancer; dyspnea; neuroblastoma; echocardiography; drug substitution; cardiomyopathy; nras gene; lisinopril; exome; trametinib; human; male; priority journal; article; treatment-related cardiotoxicity
Journal Title: Journal of Pediatric Hematology/Oncology
Volume: 37
Issue: 6
ISSN: 1077-4114
Publisher: Lippincott Williams & Wilkins  
Date Published: 2015-08-01
Start Page: e381
End Page: e383
Language: English
DOI: 10.1097/mph.0000000000000364
PROVIDER: scopus
PUBMED: 26181424
Notes: Export Date: 2 September 2015 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Shakeel Modak
    181 Modak